Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. - Wikidata - awgldk - TriplyDB

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

http://www.wikidata.org/entity/Q34635527

about

Vaccinology in the third millennium: scientific and social challenges Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive Review Vaccination of Adult Patients with Systemic Lupus Erythematosus in Portugal Herpes Zoster: the rationale for the introduction of vaccination in Italy Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective Revised adult immunization guideline recommended by the korean society of infectious diseases, 2014.Vaccination against herpes zoster in developed countries: state of the evidence Evaluation of efficacy and effectiveness of live attenuated zoster vaccine Reducing the burden of Herpes Zoster in Italy Herpes zoster and postherpetic neuralgia in older adults Varicella zoster vaccines and their implications for development of HSV vaccines Statin use and the risk of herpes zoster: a nested case-control study using primary care data from the U.K. Clinical Research Practice Datalink Vaccination in elite athletes.Cost-effectiveness of vaccination against herpes zoster.Physician Attitudes toward the Herpes Zoster Vaccination in South Korea.Clinical practice: Herpes zoster Herpes zoster: diagnostic, therapeutic, and preventive approaches.Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.Update on recommendations for use of herpes zoster vaccine.Population-based study of the epidemiology of herpes zoster in Korea.Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.Herpes zoster surveillance using electronic databases in the Valencian Community (Spain).The humanistic, economic and societal burden of herpes zoster in Europe: a critical review Burden of herpes zoster and post-herpetic neuralgia in Sweden.Annual incidence rates of herpes zoster among an immunocompetent population in the United States.Herpes zoster and postherpetic neuralgia in Catalonia (Spain)Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany The burden of disease of Herpes Zoster in Tuscany.Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.Breast implant extrusion related to Herpesviridae.Varicella-zoster virus-specific enzyme-linked immunospot assay responses and zoster-associated pain in herpes zoster subjects Effector and Central Memory Poly-Functional CD4(+) and CD8(+) T Cells are Boosted upon ZOSTAVAX(®) Vaccination A 69-year-old man with a painful vesicular rash Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition.Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.Zoster vaccine

P2860

Q24261399-6BE94683-1CA9-49B0-8D8E-D55CEF15AED5 Q26748712-AC26D359-3B97-4B14-B9B3-25090976385F Q26749096-77C56D22-0569-42D1-8F6B-FBDF4B4AB30E Q26770662-D7C0AFAD-70AF-48A1-BD09-2C0A16681CC5 Q26781940-4254AD0D-0F92-4FE6-AF1D-A6DB12FE5E07 Q26821898-B673AB52-763A-49DB-B202-2D50F2E616AB Q26862748-68680F74-D042-4C17-8792-EE9DD2D98050 Q26866473-6B4F735B-DFDB-47AD-8C8B-7A5B51E5460C Q26998625-41B89F46-96BA-4628-812A-90EB28444058 Q28111717-292A7777-E382-48EE-A10D-44D2D3E7D4BC Q28280820-CDE042E2-95C5-4749-909A-C804756EEB28 Q31107524-B13554AD-53E5-480E-9A31-D702EB7D96F4 Q34227424-71DE3472-C271-47A8-8F93-D4B2CBF1EA56 Q34291150-4B01D42E-D986-48EC-84F3-570BA7EF9415 Q34303953-5B05E857-DDFB-4864-991C-80B9931A8E7F Q34358014-DFDCDDFC-49B0-4A65-9C07-3B4F202585BC Q34376752-A395AC1D-B58B-4625-9DD6-E9C6760C98B8 Q34430200-BE32067E-7F08-4AD5-86C2-E924B28DED3B Q34434432-3F7A9587-2C2C-44ED-BFBB-F914C7528C43 Q34592021-DF6D7FFB-01E8-496B-8D38-AF5780201103 Q34667717-9934CCC7-67FE-40C3-AA4C-90ADFE28CAF4 Q35000186-0C07F724-A487-4A80-8839-7A057D9AC140 Q35008196-F69A3A0E-50E6-476F-B397-4A9FF6452AE1 Q35147612-4CC0EB29-D854-43AF-B541-873422D2F262 Q35639805-47E2955F-3492-4C3B-B91E-0A3E1344101E Q35834938-F8AA76E4-A614-463C-A76D-02147182516B Q35887209-62DEAA76-8E3D-439B-982B-83B6A533F9F2 Q35887517-B85DBF92-B3FD-4252-8C1E-D9BA2478540E Q35887530-57505ECC-5E08-4675-8DB7-14322C606E6C Q35887721-DB2881AD-B0B7-49B6-83FB-C8D0CD0036B9 Q35997398-A025783D-EBE4-4F00-9D05-8CA7DCA03847 Q36024466-9EFFD3A4-06A8-4199-BB98-67263F4D941E Q36149133-CBA262E1-4C3A-4D3E-8896-D484D5F82CDB Q36191676-BDEBC96F-9827-4720-B78D-FFEA37AE49CD Q36237622-63E5AF4A-5704-4A92-A898-8FE94F9BD77F Q36247384-BEFD2DAB-CDBE-4C4A-A30F-1AC6BA8717B6 Q36407392-DD6ACDA5-B55F-4EB0-B4A5-5E4374E80076 Q36461527-BD4EE749-7618-46EA-B993-B9F131147E7D Q36601101-985157FD-69D2-4D86-9381-C609F397C2F9 Q36623149-4C4CD88D-7DC4-4917-A50B-634B030D1347

P2860

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

http://www.wikidata.org/entity/Q34635527

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

@ast

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

@en

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

@nl

type

label

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

@ast

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

@en

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

@nl

prefLabel

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

@ast

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

@en

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

@nl

P1433

Q34635527-4B83B6FB-FB2F-4A0B-AC07-BDF3B596304B

P1476

Q34635527-10B8DD56-43F7-4703-A682-F92049BB5DC1

P2093

Q34635527-0A4A0D1B-1521-44DF-9080-645D787D346A

Q34635527-14CAF6EA-E2EF-4314-A235-EAB0AA1AFA7B

Q34635527-2B5C8CE6-0851-4F38-9A44-D089EDDC4DBA

Q34635527-488B9EC2-2BC3-4F1D-90E7-954E43AF85AC

Q34635527-5D736DD3-58E3-498B-9107-DCFB2E679E9E

Q34635527-75688ABC-F6E5-4C2E-846E-B5677DB6F2D0

Q34635527-8AE334F3-B88F-4003-9EB5-4FEAFEBD66B4

Q34635527-A49778F9-D9A1-4FE5-9103-38452A2946A7

Q34635527-AF94F300-C71C-4292-9288-1F0EFA46404A

Q34635527-B5646A39-2381-4644-B29D-0AC29ACCEC5D

P2860

Q34635527-085E6F28-55DB-4814-AB1D-93ACD7B2FA7E

Q34635527-176E8AA5-087F-456B-BF5F-50350E3DF3EF

Q34635527-1D016203-17D5-4638-85EE-4A50BF84571B

Q34635527-1F583891-365F-4691-9DEE-69546E05678C

Q34635527-2BC1BF5C-A3D7-44F1-8CB5-8D3C321DA2A8

Q34635527-39D685FD-0F55-401A-BF62-A5550C8B81CB

Q34635527-40F18A2C-DD89-41E6-B0C4-F15DBEC1265A

Q34635527-4D737377-C97F-4DFE-9AAD-9FE9D34141EA

Q34635527-4DDA8DF1-92D0-4D18-97EA-8CD39811B395

Q34635527-4FB17DA7-B9FC-4703-AEB4-32883E34C7EA

P304

Q34635527-9DB857C4-306B-47EB-B828-77A700C0F397

P31

Q34635527-2F73D25D-D915-4422-99FB-FAC091F6753C

P356

Q34635527-27ACE02B-043E-4037-B713-BD61C6641909

P407

Q34635527-1989F1F8-4BC1-4DA4-9472-B961D264003F

P433

Q34635527-A5D6F567-CEC1-4F3F-8C0E-78F20CC42B5E

P478

Q34635527-C1185037-CFBE-43A8-AF46-B88231049926

P50

Q34635527-CC0D4F24-AFCC-4797-AC43-963FAD4209E8

P577

Q34635527-2B3B623F-C58F-4C6E-BA65-4E5D93D1F3A7

P5875

Q34635527-9543493A-DBCB-4FA7-8688-65BC44F0DCA1

P698

Q34635527-7204E49B-D7AD-40A9-B1C6-7EE705C69792

P932

Q34635527-CCBD7636-6782-4188-BF05-A196169110E4

P356

P1433

Clinical Infectious Diseases

P1476

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

@en

P2093

Ivan S F Chan

http://www.w3.org/2001/XMLSchema#string

Janie Parrino

http://www.w3.org/2001/XMLSchema#string

John W Gnann

http://www.w3.org/2001/XMLSchema#string

Jon E Stek

http://www.w3.org/2001/XMLSchema#string

Kenneth E Schmader

http://www.w3.org/2001/XMLSchema#string

Myron J Levin

http://www.w3.org/2001/XMLSchema#string

Nickoya D Bundick

http://www.w3.org/2001/XMLSchema#string

Paula W Annunziato

http://www.w3.org/2001/XMLSchema#string

Robert F Betts

http://www.w3.org/2001/XMLSchema#string

Shu-Chih Su

http://www.w3.org/2001/XMLSchema#string

P2860

Analgesic therapy in postherpetic neuralgia: a quantitative systematic review.

THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS

A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

Acute Pain in Herpes Zoster and Its Impact on Health-Related Quality of Life

Recommendations for the Management of Herpes Zoster

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.

The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.

Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults

P304

922-928

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIR970

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Shelly A McNeil

P577

2012-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221792509

http://www.w3.org/2001/XMLSchema#string

P698

22291101

http://www.w3.org/2001/XMLSchema#string

P932

4542655

http://www.w3.org/2001/XMLSchema#string